Biovaccines Nigeria appoints Azoji as COO
Matthew Azoji has been appointed Chief Operating Officer/ Executive Director of Biovaccines Nigeria Limited.Until his appointment, Azoji was the Managing Director and chief executive of CHAN Medi-Pharm Ltd/Gte Jos, Plateau State. He will lead the executive team and will be responsible for the day-to-day running of the business. The appointment takes effect September 1, 2018.
Biovaccines Nigeria Limited (BVNL) is a joint venture between the Federal Government of Nigeria (FGN), and May & Baker Nigeria Plc. (MBN). It was incorporated in 2005 as the Special Purpose Vehicle to revive vaccines production activity in Nigeria.
The company is owned 51 per cent by MBN and 49 per cent by the FGN. The objective of Biovaccines Nigeria Limited is to produce safe and affordable human vaccines for Nigeria.
Create a regional center for vaccine production in West Africa and position Nigeria as a global player in vaccine business.
Azoji graduated in 1985 with a first class honours in Pharmacy from the Obafemi Awolowo University, Ile-Ife, and went on to obtain an MBA (Marketing) in 1999 from the Enugu State University of Science and Technology, Enugu. He was in the 2003 Advanced Management Programme (AMP) of the Lagos Business School. Mr. Azoji also holds certificates in Pharmaceutical Policy Analysis and Pharmacoeconomics from Utrecht University, The Netherlands, a WHO Collaboration Centre, as well as M.Sc. (Public Health) from the University of London, International Programmes.
Azoji’s other qualifications include M.Phil. (Pharmacy Administration) from the Obafemi Awolowo University, Ile-Ife, and a PhD (Clinical Pharmacy & Pharmacy Practice) in view from the University of Jos, Jos, Plateau State.He commenced his career as a Medical representative in Astra-Arewa Pharmaceuticals Ltd, Kano in 1987 and later joined May & Baker Nigeria Plc. in 1988, where he spent 12 years working in various positions.